Abstracts

International Society for Pediatric and Adolescent Diabetes

24th Annual Meeting, Zurich, Switzerland, September 14–17, 1998

Organizing Committee:
Eugen J. Schoenle, Chairman
Nadine Traber-Burkhardt, Congress Office
Rahel Nufer
Andrea Brunner
Denise Schoenle
Toni Torresani
Daniel Konrad

Scientific Committee:
Eugen J. Schoenle, Chairman
Mariarosaria Lang-Muritano
Eberhard Heinze
Henrik Mortensen
Hans K. Åkerblom
1 Severe Hypoglycaemia (SH) in Diabetic Children Treated with Multiple Insulin Regimen (MIR)
B. Adinolfi, G. Chiari, C. Cápuno, P. Zanasi, G. Costi, M. Vanelli
Department of Pediatrics, Diabetes Unit, University of Parma, Italy

The aim of our study was to assess the prevalence and characteristics of SH (altered consciousness, coma, seizures or other neurologic symptoms) in type 1 diabetic children and adolescents treated with MIR attending our outpatient department, in a retrospective study from 01/01/90 to 31/12/97. We obtained the information on hypoglycemic events from clinical reports and questionnaires compiled by patients’ parents. 188 diabetic patients (95 females and 93 males), 16.2 ± 6.7 years old (duration of diabetes 8 ± 5.3 years), were studied. They were divided into two groups: 160 non-SH children and 28 patients that experienced 38 SH (2 had four and 4 two episodes). No difference in chronological age, duration of diabetes, metabolic control and number of daily insulin injections was found. 45% of SH occurred in patients aged 7–14 years, 42% in patients younger than 7 years of age, and 13% in those older than 14 years of age. 24/38 episodes of SH occurred in children on a daily insulin dose ranging from 0.6 to 0.8 U/kg; 13/27 SH in patient on insulin dose >0.8 U/kg/die and SH in patients on a daily insulin dose <0.6 U/kg. SH was experienced predominantly in spring (n = 13) and summer time (n = 13). 50% of SH were nocturnal. Patients/parents were able to identify the cause of 15 SH. The predominant cause was incorrect food intake (73%), particularly in a population with a mean age of 14.3 years. SH was associated with loss of consciousness in 27/38, with seizures in 7 and transient hemiparesis in 2 patients. SH was announced by proclusions in just 39% of patients (19% trembling). 82% of SH were treated with administration i.m. glucagon and 8% with i.v. 33% glucose. Severe hypoglycemia is a recurrent problem, not related to metabolic control or to daily insulin dose, and diabetic children with a history of severe hypoglycemia are at risk to experience future episodes.

2 Nocturnal Hypoglycaemia in Danish Children with Type 1 Diabetes mellitus: A Nationwide Study
O. Andersen, M. Sørensen, P. Hougaard, H.B. Mortensen, Danish Study Group of Diabetes in Children Hillerød Hospital, Hillerød, Denmark

The aim of the study was to identify predictors and evaluate the risk of nocturnal hypoglycaemia (NHG) in children and adolescents with IDDM during everyday life. All diabetics treated in paediatric departments in Denmark were invited to participate. Basic characteristics and treatment were recorded and HbA1c was determined centrally. Blood samples for analysis of blood glucose (BG) were taken in capillary tubes at home and mailed to one laboratory. BG was measured during 24 h in the fasting state, before main meals, at bedtime, at 3 a.m. and the following morning. Hypoglycaemia (HG) was defined as BG <3.5 mM. Data were analysed by logistic regression using backwards stepwise exclusion. p < 0.05 was considered significant. Results are given as mean (SD) BG in mM. Of 1,009 eligible patients 464 patients completed the blood sampling including the nocturnal sample. HbA1c was 8.46% (1.27).

HG was observed on at least one occasion in 23.5% of the patients. The frequency was highest at night. Significant relations were found between NHG and BG at bedtime (p < 0.001), male sex (p < 0.02), age (p < 0.05), small height (p < 0.05), ≤2 injections/day when compared to ≥3 (p < 0.05) and the dose of rapid-acting evening insulin (p < 0.05). A significant relation was found between NHG and BG the next morning (p < 0.001). Relations between HbA1c, pubertal stage, hypox, sport activities were not significant. The data suggest that the risk of NHG is associated to male sex, young age, high evening dose of rapid-acting insulin and low BG at bedtime. Low BG in the morning may indicate preceding NHG.

3 Central Adiposity and Insulin Sensitivity in Healthy African-American Children
S. Arslanian, K. Danadian, V. Lewy, C. Suprasongsin, M. Meza
Children’s Hospital, University of Pittsburgh, Pa., USA

Abdominal adiposity has been implicated as a risk factor for insulin resistance and NIDDM in adults. African-Americans (AA) are at increased risk for obesity, CVD, hypertension and NIDDM. We have shown that healthy AA children are insulin resistant and have higher insulin secretion compared with their White peers [J Pediatr 129:1996; J Clin Endocrinol Metab 82:1997]. Moreover, AA children are more obese with central distribution of fat compared with their White peers. Therefore, the aim of the present investigation was to study the relationship of central obesity to insulin resistance in AA children. We studied 19 (10 male, 9 female) healthy AA prepubertal children, age (9.8 ± 0.2 years), BMI (19.6 ± 1.0 kg/m²). Body composition was assessed with DEXA, and abdominal adiposity by CT scan at the level of L4, with measurements of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT). Insulin action was...
assessed by a 3-hour hyperinsulinemic (40 mU/m²/min)-euglycemic clamp. Insulin-stimulated glucose disposal (Rd) was calculated over the last 30 min of the clamp.

Results: Mean ± SEM.

<table>
<thead>
<tr>
<th></th>
<th>Males</th>
<th>Females</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI, kg/m²</td>
<td>19.4 ± 1.4</td>
<td>19.9 ± 1.5</td>
<td>n.s.</td>
</tr>
<tr>
<td>%BF</td>
<td>20.4 ± 3.8</td>
<td>24.7 ± 3.5</td>
<td>n.s.</td>
</tr>
<tr>
<td>VAT/SAT ratio</td>
<td>0.3 ± 0.1</td>
<td>0.2 ± 0.02</td>
<td>n.s.</td>
</tr>
<tr>
<td>Rd, mg/kg/min</td>
<td>13.4 ± 1.4</td>
<td>10.0 ± 1.3</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

Rd correlated with %BF (r = –0.76, p = 0.0005), SAT (r = 0.80, p = 0.005) and VAT (r = –0.71, p = 0.001). However, in a multiple regression analysis SAT was the only significant determinant of RD explaining 64% of its variability independent of %BF.

We conclude that the risk of abdominal obesity to insulin resistance is already established in the first decade of life in AA children. It remains to be determined if this risk is of greater magnitude than that in American-White children.

The incidence of childhood diabetes is low in Iceland compared to the other Nordic countries. Of special interest is the difference in incidence between Norway and Iceland in light of the alleged Norwegian origin of the Icelandic population. The incidence of IDDM in Iceland is close to 10/100,000/year, or less than half of the reported incidence in Norway. A major part of the genetic predisposition is believed to be encoded in the HLA complex residing on chromosome 6. A strong association has been found with certain alleles of the HLA-DR and DQ genes in the MHC class II region. Some studies suggest that there may be other loci in the HLA gene complex that play a role. The genetic background of the diabetic population in Iceland and in Norway has not been previously compared with respect to HLA allelic distribution and frequency. We genotyped the DRB locus of unrelated Icelandic IDDM patients diagnosed before 15 years of age and of unrelated control samples from the Icelandic population. PCR amplification and dot blot hybridisation method was performed with oligoprobes distinguishing between 18 different alleles of the DRB gene. The results from genotyping of 60 patients and 183 controls show no major differences in DRB allelic distribution between Icelandic and Norwegian patients and between control groups of both countries. Specifically the frequency of DR301 (48 vs. 54%), DR401 (60 vs. 59%) and DR404 (20 vs. 25%) Iceland vs. Norway, respectively. More patients are being genotyped at the DRB and DQ genes and genotyping of the DQ genes is in progress. These first results indicate that the difference in incidence of childhood diabetes seen between Iceland and Norway can not be explained by a major difference in the DRB allelic distribution. An explanation must be sought elsewhere.

4

Childhood Diabetes in Iceland: Genotyping of the DRB Gene

V.M. Backman, J.R. Gulkcher, A.C. Fasquel, H. Andraison, K. Kristjansson, K. Stefansson, A.V. Thorsson

a DeCode Genetics, and b Department of Pediatrics, Reykjavik Hospital, University of Iceland, Reykjavik, Iceland

The incidence of childhood diabetes is low in Iceland compared to the other Nordic countries. Of special interest is the difference in incidence between Norway and Iceland in light of the alleged Norwegian origin of the Icelandic population. The incidence of IDDM in Iceland is close to 10/100,000/year, or less than half of the reported incidence in Norway. A major part of the genetic predisposition is believed to be encoded in the HLA complex residing on chromosome 6. A strong association has been found with certain alleles of the HLA-DR and DQ genes in the MHC class II region. Some studies suggest that there may be other loci in the HLA gene complex that play a role. The genetic background of the diabetic population in Iceland and in Norway has not been previously compared with respect to HLA allelic distribution and frequency. We genotyped the DRB locus of unrelated Icelandic IDDM patients diagnosed before 15 years of age and of unrelated control samples from the Icelandic population. PCR amplification and dot blot hybridisation method was performed with oligoprobes distinguishing between 18 different alleles of the DRB gene. The results from genotyping of 60 patients and 183 controls show no major differences in DRB allelic distribution between Icelandic and Norwegian patients and between control groups of both countries. Specifically the frequency of DR301 (48 vs. 54%), DR401 (60 vs. 59%) and DR404 (20 vs. 25%) Iceland vs. Norway, respectively. More patients are being genotyped at the DRB and DQ genes and genotyping of the DQ genes is in progress. These first results indicate that the difference in incidence of childhood diabetes seen between Iceland and Norway can not be explained by a major difference in the DRB allelic distribution. An explanation must be sought elsewhere.

6

Validation of a Multidimensional Quality-of-Life Measure for Children and Adolescents with Insulin-Dependent Diabetes mellitus (IDDM)

B. Bartsch, P. F. Schlottke, W. Kieß

a Olghospital Stuttgart, b University of Tübingen, c University of Leipzig, Germany

The aim of this multicenter study was to develop and assess the psychometric properties of a quality-of-life measure for children and adolescents with IDDM. Quality of life was defined as perceived satisfaction/difficulty in three different key domains of life: (1) diabetes-related social differences (6 items); (2) diabetes-related barriers (7 items); (3) diabetes-related future worries (6 items). Item scores ranged from 1 (low quality of life) to 4 (high quality of life). A total of 78 patients (36% boys) from 6 German pediatric centers (Bonn, Frankfurt, Giessen, Hannover, Leipzig, Stuttgart) com-

The identification of predictors of imminent development of IDDM in subjects at risk for the development of the disease is a major goal that must precede the initiation of preventive therapies. In order to assess whether T cell responses to autoantigens could fulfill this role, we compared responses to 11 test antigens or peptides in high-risk first-degree relatives or to other antigens. The acquisition of T-cell responses to PI and/or IA2 in high-risk relatives and new-onset cases is similar. In the former, the frequency is significantly greater than responses to PI and/or IA2 in high-risk relatives or to other antigens. The acquisition of autoantibodies, particularly in subjects without high risk HLA genes.

<table>
<thead>
<tr>
<th>% Positives</th>
<th>HSP</th>
<th>GAD</th>
<th>p69/BSA</th>
<th>PI/IA2</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDR</td>
<td>9</td>
<td>28</td>
<td>37</td>
<td>37</td>
</tr>
<tr>
<td>High risk</td>
<td>8</td>
<td>36</td>
<td>50</td>
<td>86</td>
</tr>
<tr>
<td>IDD onset</td>
<td>12</td>
<td>55</td>
<td>73</td>
<td>82</td>
</tr>
<tr>
<td>0.5 years</td>
<td>10</td>
<td>58</td>
<td>76</td>
<td>75</td>
</tr>
<tr>
<td>1 year</td>
<td>11</td>
<td>54</td>
<td>75</td>
<td>75</td>
</tr>
</tbody>
</table>